Donepezil: Difference between revisions
Jump to navigation
Jump to search
NCLEX nursing pharmacology monographs — batch import |
Add medication infobox (Drugbox) to monographs |
||
| Line 1: | Line 1: | ||
{{Drugbox | |||
| name = Donepezil | |||
| brand = Aricept | |||
| therapeutic = Anti-Alzheimer | |||
| pharmacologic = Cholinesterase inhibitor | |||
| onset = Effect over weeks; once daily. | |||
| halflife = Half-life about 70 hours; level not routine. | |||
| routes = PO (oral) | |||
| highalert = No | |||
| blackbox = None | |||
| antidote = Atropine for severe cholinergic effects. | |||
| pregnancy = Not typically used. | |||
}} | |||
<div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;"> | <div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;"> | ||
''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.'' | ''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.'' | ||
Latest revision as of 16:09, 17 June 2026
| Drug monograph · NCLEX study reference | |
| Trade names | Aricept |
|---|---|
| Therapeutic class | Anti-Alzheimer |
| Pharmacologic class | Cholinesterase inhibitor |
| Onset / peak / duration | Effect over weeks; once daily. |
| Half-life / level | Half-life about 70 hours; level not routine. |
| Routes | PO (oral) |
| High-alert (ISMP) | No |
| Black box warning | None |
| Antidote / reversal | Atropine for severe cholinergic effects. |
| Pregnancy / lactation | Not typically used. |
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Donepezil (brand name Aricept) — Anti-Alzheimer; Cholinesterase inhibitor.
Identification
- Therapeutic class: Anti-Alzheimer.
- Pharmacologic class: Cholinesterase inhibitor.
Pharmacology
- Mechanism of action: Inhibits acetylcholinesterase to raise acetylcholine and support cognition.
- Onset / peak / duration: Effect over weeks; once daily.
- Half-life / therapeutic level: Half-life about 70 hours; level not routine.
Clinical use
- Indications: Alzheimer dementia (all stages).
- Usual dose, route, frequency: 5 to 10 mg PO at bedtime; ODT available.
- Maximum dose / adjustments: Titrate to tolerance.
Safety
- Contraindications: Hypersensitivity.
- Black box warning: None.
- Interactions: Anticholinergics oppose effect, beta blockers (bradycardia), NSAIDs (GI bleeding).
- Pregnancy / lactation: Not typically used.
- High-alert: No.
Adverse effects
- Common side effects: Nausea, diarrhea, insomnia, vivid dreams.
- Serious effects to report: Bradycardia, syncope, GI bleeding.
- Antidote / reversal: Atropine for severe cholinergic effects.
Nursing process
- Assessment before administration: Heart rate, cognitive baseline, GI and ulcer history.
- Interventions during therapy: Monitor heart rate and GI symptoms.
- Monitor: Cognition, heart rate, GI tolerance.
- Evaluation / expected outcome: Slowed cognitive decline.
Patient teaching
- Patient teaching: Take at bedtime; effects are gradual.
- Notify provider if: Fainting, slow heartbeat, black stools.
- Administration tips: Bedtime; with or without food.